Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) – Analysts at Wedbush lifted their Q4 2022 earnings per share estimates for Kiniksa Pharmaceuticals in a report issued on Wednesday, August 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($1.46) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q1 2023 earnings at ($0.29) EPS, Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.45) EPS, Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($1.63) EPS, FY2024 earnings at ($1.46) EPS and FY2025 earnings at ($0.89) EPS.
Get Kiniksa Pharmaceuticals alerts:Kiniksa Pharmaceuticals Stock Up 14.7 %
Shares of KNSA opened at $13.41 on Monday. Kiniksa Pharmaceuticals has a 12-month low of $7.36 and a 12-month high of $15.24. The firm has a market capitalization of $928.99 million, a PE ratio of -8.28 and a beta of -0.12. The stock's fifty day simple moving average is $9.96 and its 200-day simple moving average is $10.02.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $44,000. Rockefeller Capital Management L.P. increased its holdings in shares of Kiniksa Pharmaceuticals by 666.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,750 shares of the company's stock worth $67,000 after acquiring an additional 5,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Kiniksa Pharmaceuticals by 290.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,164 shares of the company's stock worth $84,000 after acquiring an additional 5,327 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $86,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $190,000. Institutional investors and hedge funds own 42.57% of the company's stock.About Kiniksa Pharmaceuticals
(Get Rating)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Articles
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- What to Expect from the Markets in a Recession
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- MarketBeat: Week in Review 8/1 – 8/5
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.